See the Northwestern University Press release on the first in human phase 0 clinical trials of Spherical Nucleic Acids.
Dr. Stegh received an R01 grant entitled “Systemic RNA interference to reactivate p53 tumor suppression” (NCI 1R01CA208783).
Dr. Stegh’s laboratory is an integral part of the Northwestern University’s Center for Cancer Nanotechnology Excellence and the Northwestern Brain Tumor Specialized Programs of Research Excellence (SPORE).
About Our Lab
Our research program is aimed at understanding the genetic program that underlies the pathogenesis of Glioblastoma multiforme (GBM), the most prevalent and malignant form of brain cancer. Applying a combination of cell/molecular biology, oncogenomic and mouse engineering approaches, we are dedicated to systematically characterize novel gliomagenic oncogenes and tumor suppressors. We will functionally delineate and validate these pathways towards pharmaceutical opportunities using sophisticated cell culture and animal models.
Please read our latest publication:
May et al., 2019. IDH3A regulates one-carbon metabolism in glioblastoma. Science Adv. Jan 2;5(1):eaat0456.
The paper is also highlighted on the Feinberg School of Medicine homepage.